BridgeBio to present late-breaking infigratinib data at ESPE 2026
BridgeBio Pharma said it will present one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia at the Annual ESPE Meeting 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.